BioCryst Pharmaceuticals, Inc.
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930ā¦ read more
Healthcare
Biotechnology
31 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.09
Price+0.85%
$0.06
1Y
Price
Market Cap
$1.493b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+17.4%
EBITDA Margin+3.1%
Net Profit Margin+25.2%
Free Cash Flow MarginRevenue
$557.506m
+23.7%
1y CAGR+27.4%
3y CAGR+38.6%
5y CAGREarnings
-$35.711m
+59.8%
1y CAGR+43.0%
3y CAGR+23.7%
5y CAGREPS
-$0.17
+60.5%
1y CAGR+45.1%
3y CAGR+26.6%
5y CAGRBook Value
-$421.594m
$457.188m
Assets$878.782m
Liabilities$738.917m
DebtDebt to Assets
161.6%
11.6x
Debt to EBITDAFree Cash Flow
$15.761m
+129.7%
1y CAGR+71.8%
3y CAGR+50.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company